ArticleWorld journal of urology2026
Aggressive stone removal in octogenarian bedridden elderly patients: analysis of safety and impact on the reduction of recurrent stone-related events.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the stone event-free survival following ureteroscopic lithotripsy (URSL) in bedridden elderly patients, including octogenarians and to identify the specific risk factors for recurrent stone events in this population.
methodsWe retrospectively analyzed the data of bedridden patients who underwent URSL for urolithiasis between January 2012 and June 2022 at our institution. The primary outcome of this study was ipsilateral stone event-free survival.
resultsThe study analyzed 203 patients including 150 female (73.9%), with a median age of 81 years. During a median follow-up period of 29 months, 53 patients (26.1%) experienced ipsilateral recurrence of stone-related events and 12 patients (5.9%) experienced contralateral stone-related events, respectively. Seventy-seven patients (37.9%) died during the study period, with a median overall survival (OS) of 67 months. The estimated 2-year and 5-year ipsilateral stone event-free survival rates were 73.5% and 62.0%, respectively. The estimated 2-year any stone event-free survival and OS rates were 71.1% and 73.4%, respectively. The presence of struvite/carbonate apatite stone was independently associated with stone recurrence as a bedridden patient–specific risk factor.
conclusionConsidering the adverse conditions specific to bedridden patients, URSL for urolithiasis is an acceptable procedure even with a high rate of stone recurrence. The identified risk factor may help guide treatment decisions for these high-risk patients.
Indexed as
Identifiers
41546702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.